{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:57:29Z","timestamp":1790326649741,"version":"4.1.0"},"reference-count":37,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Diagnosis of malignant mesothelioma is more common in the chest than it is in the abdomen. Most published immunohistochemistry data are more applicable to pleural than to peritoneal mesothelioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To clarify the practical utility of 17 immunohistochemistry markers in the differential diagnosis of peritoneal mesothelioma with an emphasis on stains for which there is either contradictory information or a paucity of literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Consultation files of peritoneal mesothelioma diagnoses rendered from 1999 to 2014 were reviewed; 244 cases were identified. The results of immunohistochemistry markers performed were tabulated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Immunohistochemistry markers positive in peritoneal mesothelioma in order of sensitivity were calretinin (244 of 244; 100%), WT1 (205 of 218; 94%), CK5\/6 (173 of 194; 89%), mesothelin (132 of 150; 88%), and D2-40 (78 of 97; 80%). Markers used to differentiate carcinoma from mesothelioma showed immunoreactivity in peritoneal mesothelioma: estrogen receptor (2 of 84; 2%), B72.3 (6 of 196; 3%), CK20 (5 of 116; 4%), CD15 (7 of 192; 4%), p63 (3 of 62; 5%), carcinoembryonic antigen (9 of 199; 5%), PAX8 (12 of 191; 6%), progesterone receptor (5 of 71; 7%), Ber-EP4 (17 of 209; 8%), and CD138 (9 of 91; 10%). BAP1 loss, increasingly used in the differential diagnosis of benign versus malignant mesothelial proliferation, occured in 55% (99 of 181) of peritoneal mesothelioma cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>The results support the experience that there is no definitive marker to rule out malignant mesothelioma, including PAX8, estrogen receptor, progesterone receptor, and p63 immunoreactivity. The high rate of immunoreactivity for mesothelin may have a role as a predictive marker for immune targeting. BAP1 loss of 55% in this cohort of peritoneal mesothelioma confirms published observations, and BAP1 retention is seen in a significant proportion of neoplastic cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2017-0092-oa","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T11:20:26Z","timestamp":1508412026000},"page":"236-242","source":"Crossref","is-referenced-by-count":72,"title":["Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases"],"prefix":"10.5858","volume":"142","author":[{"given":"Radhika Theresa","family":"Tandon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuis","family":"Jimenez-Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain C.","family":"Borczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"issue":"8","key":"2020081219494564400_i1543-2165-142-2-236-b01","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2020081219494564400_i1543-2165-142-2-236-b02","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3978\/1053","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"issue":"6","key":"2020081219494564400_i1543-2165-142-2-236-b03","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/oem.2005.023200","article-title":"The French National Mesothelioma Surveillance Program","volume":"63","author":"Goldberg","year":"2006","journal-title":"Occup Environ Med"},{"issue":"5","key":"2020081219494564400_i1543-2165-142-2-236-b04","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5858\/arpa.2012-0214-oa","article-title":"International Mesothelioma Interest Group. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2020081219494564400_i1543-2165-142-2-236-b05","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/modpathol.2012.200","article-title":"Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas","volume":"26","author":"Ord\u00f3\u00f1ez","year":"2012","journal-title":"Mod Pathol"},{"issue":"3","key":"2020081219494564400_i1543-2165-142-2-236-b06","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.mp.0000056981.16578.c3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Mod Pathol"},{"key":"2020081219494564400_i1543-2165-142-2-236-b07","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"issue":"10","key":"2020081219494564400_i1543-2165-142-2-236-b08","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.prp.2016.07.010","article-title":"Pathology reporting of malignant pleural mesothelioma first diagnosis: a population-based approach","volume":"212","author":"Ascoli","year":"2016","journal-title":"Pathol Res Pract"},{"issue":"3","key":"2020081219494564400_i1543-2165-142-2-236-b09","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/pap.0b013e318253465d","article-title":"Value of PAX 8 immunostaining in tumor diagnosis: a review and update","volume":"19","author":"Ord\u00f3\u00f1ez","year":"2012","journal-title":"Adv Anat Pathol"},{"issue":"7","key":"2020081219494564400_i1543-2165-142-2-236-b10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.humpath.2014.03.006","article-title":"Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study","volume":"45","author":"Ord\u00f3\u00f1ez","year":"2014","journal-title":"Hum Pathol"},{"issue":"8","key":"2020081219494564400_i1543-2165-142-2-236-b11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/modpathol.2013.34","article-title":"Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma","volume":"26","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Mod Pathol"},{"issue":"1","key":"2020081219494564400_i1543-2165-142-2-236-b12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2015","journal-title":"Mod Pathol"},{"key":"2020081219494564400_i1543-2165-142-2-236-b13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2015.12.012","article-title":"Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma","volume":"51","author":"Andrici","year":"2016","journal-title":"Hum Pathol"},{"issue":"24","key":"2020081219494564400_i1543-2165-142-2-236-b14","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.ccr-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2020081219494564400_i1543-2165-142-2-236-b15","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.ccr-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020081219494564400_i1543-2165-142-2-236-b16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00432-013-1408-2","article-title":"Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma","volume":"139","author":"Pillai","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"2020081219494564400_i1543-2165-142-2-236-b17","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1158\/0008-5472.can-08-4523","article-title":"Estrogen receptor-\u03b2 affects the prognosis of human malignant mesothelioma","volume":"69","author":"Pinton","year":"2009","journal-title":"Cancer Res"},{"issue":"4","key":"2020081219494564400_i1543-2165-142-2-236-b18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1365-2559.2002.14044.x","article-title":"Foamy cell mesothelioma","volume":"41","author":"Cavazza","year":"2002","journal-title":"Histopathology"},{"issue":"5","key":"2020081219494564400_i1543-2165-142-2-236-b19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.humpath.2005.02.014","article-title":"Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases","volume":"36","author":"Ord\u00f3\u00f1ez","year":"2005","journal-title":"Hum Pathol"},{"issue":"37","key":"2020081219494564400_i1543-2165-142-2-236-b20","doi-asserted-by":"publisher","first-page":"59314","DOI":"10.18632\/oncotarget.10653","article-title":"Positive nuclear BAP1 immunostaining helps differentiate non\u2013small cell lung carcinomas from malignant mesothelioma","volume":"7","author":"Carbone","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"2020081219494564400_i1543-2165-142-2-236-b21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/modpathol.2009.88","article-title":"Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study","volume":"22","author":"Tong","year":"2009","journal-title":"Mod Pathol"},{"issue":"6","key":"2020081219494564400_i1543-2165-142-2-236-b22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/pas.0b013e318216c112","article-title":"A comprehensive analysis of PAX8 expression in human epithelial tumors","volume":"35","author":"Laury","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2020081219494564400_i1543-2165-142-2-236-b23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/pas.0b013e3181da7687","article-title":"PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma","volume":"34","author":"Laury","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2020081219494564400_i1543-2165-142-2-236-b24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/pat.0b013e3283631cce","article-title":"Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy","volume":"45","author":"Lee","year":"2013","journal-title":"Pathology"},{"issue":"9","key":"2020081219494564400_i1543-2165-142-2-236-b25","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"issue":"10","key":"2020081219494564400_i1543-2165-142-2-236-b26","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/modpathol.2015.87","article-title":"Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology","volume":"28","author":"Andrici","year":"2015","journal-title":"Mod Pathol"},{"issue":"10","key":"2020081219494564400_i1543-2165-142-2-236-b27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"issue":"1","key":"2020081219494564400_i1543-2165-142-2-236-b28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"issue":"9","key":"2020081219494564400_i1543-2165-142-2-236-b29","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.humpath.2010.03.002","article-title":"Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter","volume":"41","author":"Tan","year":"2010","journal-title":"Hum Pathol"},{"issue":"2","key":"2020081219494564400_i1543-2165-142-2-236-b30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4291\/wjgp.v7.i2.218","article-title":"Clinical impacts of mesothelin expression in gastrointestinal carcinomas","volume":"7","author":"Einama","year":"2016","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"1","key":"2020081219494564400_i1543-2165-142-2-236-b31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1309\/8fch-q3vp-bwm7-b5x9","article-title":"Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum","volume":"125","author":"Barnetson","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2020081219494564400_i1543-2165-142-2-236-b32","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/pas.0b013e318033e7a8","article-title":"H-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of Immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary","volume":"31","author":"Comin","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2020081219494564400_i1543-2165-142-2-236-b33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/modpathol.3800827","article-title":"Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary m\u00fcllerian system origin?","volume":"20","author":"Tong","year":"2007","journal-title":"Mod Pathol"},{"issue":"4","key":"2020081219494564400_i1543-2165-142-2-236-b34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/modpathol.3800067","article-title":"Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers","volume":"17","author":"Trupiano","year":"2004","journal-title":"Mod Pathol"},{"issue":"11","key":"2020081219494564400_i1543-2165-142-2-236-b35","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.humpath.2005.08.008","article-title":"Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas","volume":"36","author":"Ord\u00f3\u00f1ez","year":"2005","journal-title":"Hum Pathol"},{"issue":"1","key":"2020081219494564400_i1543-2165-142-2-236-b36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/dc.20747","article-title":"Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5\/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions","volume":"36","author":"Pu","year":"2008","journal-title":"Diagn Cytopathol"},{"issue":"10","key":"2020081219494564400_i1543-2165-142-2-236-b37","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1158\/1535-7163.mct-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol Cancer Ther"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/2\/236\/1447929\/arpa_2017-0092-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/2\/236\/1447929\/arpa_2017-0092-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:34:51Z","timestamp":1764790491000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/142\/2\/article-p236.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,10,19]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2017-0092-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]}}}